Top 7 Wound Care Companies in Advanced Wound Care Market

Published: May 2024

In the last decade, wound care has contributed to a significant global healthcare strain, driven by the high financial cost of management and intensive utilization of healthcare personnel. In fact, research suggests that global spending on wound care exceeds USD 140 Billion, annually, while the US Medicare costs alone for chronic wound care are estimated to be at USD 22.5 Billion. Therefore, in order to address this challenge, innovators have gradually shifted towards developing innovative and technologically advanced wound care products, that allow effective and expedited wound care management.

Further, in order to increase the adoption of advanced wound care products, stakeholders are actively integrating such products with automation tools, artificial intelligence and machine learning. These initiatives have led to the development of smart bandages and mobile-operated wound care products. Such innovation in the wound care domain, coupled with the growing partnership activity, the wound care market is anticipated to gain widespread popularity in the coming years.

Despite the potential of such solutions in enhanced wound care management, there are still some challenges associated with the adoption of such products / solutions, including competition from conventional wound care solutions, lack of awareness, perception of high-costs associated with advanced solutions and limited availability in developing nations. In this context, advanced wound care products / solutions providers are actively exploring advanced technologies and are heavily investing in research and development of advanced wound care solutions, demonstrating the huge revenue generation potential of utilizing these management solutions.

Roots Analysis has conducted an exhaustive study on Advanced Wound Care Market featuring the current market landscape and future opportunity for the wound care companies providing product / solution providers in the advanced wound care domain, over a span of 10 years.

Top Seven Advanced Wound Care Companies

Ethicon (a subsidiary of Johnson & Johnson)
Fidia Farmaceutici
Integra Life Sciences
Mölnlycke Health Care
Smith + Nephew
Solventum
Zimmer Biomet

The figure below highlights the top seven advanced wound care product providers:

Top 7 Companies to Watch Advanced Wound Care Market

Interested in exploring all 240+ players engaged in offering advanced wound care products, along with their recent initiatives?

Discover Below the Details on Top 7 Advanced Wound Care Product Providers

Let us dive deep into the details of the top 7 advanced wound care product providers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Coloplast

Company Overview

Coloplast is a healthcare company focused on the development of products for intimate healthcare needs. Within the wound and skin care segment, the company is currently focused on manufacturing wound care dressings, and bioengineered skins and dermal substitutes.

With a workforce of over 16,500 employees worldwide, Coloplast has its production facilities in China, Costa Rica, France, Germany, Hungary, and Sweden. Additionally, the company claims to have a strong business presence across more than 30 countries.

The company is known for its strong emphasis on user-centric innovation and high-quality medical products that improve quality of life for patients with intimate care requirements. Further, it continues to invest in R&D to expand its offerings in advanced wound management and personal health technologies.

Advanced Wound Care Product Portfolio

The section provides information on Coloplast’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Hydrogel Dressings, Alginate Dressings and Hydrocolloid Dressings

Types of Acute Wounds Treated: Surgical Wounds, Burns, lacerations, Skin Abrasions, Graft and Donor Sites, Post Operative Surgical Wounds

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers, Venous and Arterial Leg Ulcers

Recent Developments

In May 2026, Coloplast received an Innovative Technology contract from Vizient for its Biatain Silicone Fit dressing. This recognition highlights the dressing’s unique qualities and potential to improve patient care and outcomes in wound management. Hospitals can now access this advanced silicone dressing, enhancing healing outcomes while reducing pain during changes.

In March 2026, Coloplast appointed Gavin Wood as its new President and Chief Executive Officer. He had previously served as Executive Vice President at Molnycke. This leadership transition marks an important step for the global medical device company as it continues to strengthen its position in intimate healthcare.

To know more about the recent initiatives of Coloplast and other advanced wound care product providers, access full report.

2. Ethicon

Company Overview

Ethicon is a wholly-owned subsidiary of Johnson & Johnson. The company’s current portfolio includes products that can be utilized for hemostasis, reflux management, tumor microwave ablation, surgical stapling, wound closure, and medical robotics. In addition, the company has developed groundbreaking medical device technologies / platforms in order to assist healthcare practitioners in the management of various clinical conditions. These include ENSEAL X1 Tissue Sealer, MONARCH Robotic Platform, and NeuWave Microwave Ablation System.

Within the wound care segment, the company is currently focused on the manufacturing of wound care dressings and skin closure systems for the treatment and management of various types of acute wounds.

Advanced Wound Care Product Portfolio

The section provides information on Ethicon’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings and Hydrophilic Wound Dressings
Advanced Wound Care Medical Devices: Skin Closure Systems / Adhesives

Types of Acute Wounds Treated: Surgical Wounds

Recent Developments

The company strengthened its advanced wound care portfolio in 2026 through the launch of the STRATAFIX Symmetric PDS Plus Knotless Tissue Control Device, an antibacterial knotless barbed absorbable suture designed to enable secure tissue approximation with uniform tension distribution and improved procedural efficiency.

Further, Ethicon received CE Mark approval for the ETHICON™ 4000 Surgical Stapler, which provides reliable staple line integrity across a broad range of tissue thicknesses for both open and minimally invasive surgeries.

To know more about the recent initiatives of Ethicon and other advanced wound care product providers, access full report.

3. Fidia Farmaceutici

Company Overview

Fidia Farmaceutici is an Italy-based healthcare company focused on the development of products pertaining to joint care, skin care, eye care, aesthetic care, and specialty care. It is worth highlighting that the company’s product portfolio comprises of 40+ prescription drugs, ~35 medical devices and 5 vaccines for various clinical conditions. With more than 1,500 employees and sales across various geographical regions, Fidia Farmaceutici is one of the leading global manufacturers of hyaluronic acid-based products.

Within the wound care segment, the company is currently focused on the development of wound care dressings, and bioengineered skins and dermal substitutes. The company is strongly committed to advancing regenerative medicine through continuous innovation and strategic partnerships.

Advanced Wound Care Product Portfolio

The section provides information on Fidia Farmaceutici’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Hydrogel Dressings and Collagen Dressings
Advanced Wound Care Bioengineered Skin and Dermal Substitutes: Autografts

Types of Acute Wounds Treated: Surgical Wounds, Burns, Abrasions and Cuts

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers and Other Chronic Wounds

Recent Developments

In April 2026, Fidia hosted the “Fidia Academy,” an international scientific event focused on modern wound management, bringing together global experts and clinicians. The program highlighted hyaluronic acid’s role in tissue regeneration and bioactive integration in complex wound care.

In May 2026, Fidia supported the release of the new EWMA document “New Technologies for Tissue Damage Repair,” which was published in the Journal of Wound Management. As a formal supporter of the European Wound Management Association (EWMA), the company contributed to this evidence-based overview of dermal matrices and regenerative technologies.

To know more about the recent initiatives of Fidia Farmaceutici and other advanced wound care product providers, access full report.

4. Integra Life Sciences

Company Overview

Integra LifeSciences is focused on the development and manufacturing of products for skin regeneration, neurosurgery, and reconstructive and general surgery. The company's advanced wound care portfolio is designed to support the management of complex acute and chronic wounds, burns, and soft tissue reconstruction by promoting tissue regeneration and facilitating effective wound closure. Leveraging its expertise in regenerative medicine and biomaterial technologies, Integra continues to expand its wound care offerings through product innovation and strategic commercial initiatives, strengthening its position in the advanced wound care market. The company also collaborates with healthcare providers to develop clinically driven products that address unmet needs in complex wound management and improve patient outcomes.

Advanced Wound Care Product Portfolio

The section provides information on Integra Life Science’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Antimicrobial Dressings, Hydrogel Dressings, Alginate Dressings, Hydrocolloid Dressings and Composite Dressings
Advanced Wound Care Medical Devices: MedE-Kast® Total Contact Casting System and TCC-EZ® Total Contact Cast System
Advanced Wound Care Bioengineered Skin and Dermal Substitutes: Autografts and Extracellular Matrix

Types of Acute Wounds Treated: Surgical Wounds, Burns, Donor and Sites Grafts, Abrasions, Lacerations and Traumatic Wounds

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers and Charcot Neuroarthropathy

Recent Developments

In April 2026, Integra LifeSciences presented new real-world evidence on its PriMatrix® Dermal Scaffold at three major wound care and burn conferences. The data, drawn from 985 cases involving 117 surgeons, demonstrated the effective use of PriMatrix, which is a fetal bovine dermal matrix, across a wide range of challenging wounds, including diabetic foot ulcers, surgical and traumatic wounds, and chronic ulcers.

In March 2026, Integra LifeSciences initiated a voluntary recall of certain MediHoney Wound and Burn products and specific lots of CVS Wound Gel. The action, classified by the FDA as a Class II recall, was due to packaging failures that could compromise the sterile barrier, potentially leading to infection risks or delays in wound care treatment. This recall affects all lots of several MediHoney Calcium Alginate dressings and gels, along with two specific lots of CVS Wound Gel.

To know more about the recent initiatives of Integra Life Sciences and other advanced wound care product providers, access full report.

5. Mölnlycke Health Care

Company Overview

Mölnlycke Health Care offers various products for wound care management and surgical requirements, including incision care, biogel gloves, barrier staff clothing and hibiclens skin cleansers. Moreover, the company supports its customers by providing products pertaining to pressure injury management, infection prevention, safe patient handling and clinician safety.

Within the advanced wound care segment, the company is focused on the development and manufacturing of wound care dressings and wound healing medical devices for both acute and chronic wounds. With a strong global presence, Mölnlycke continues to invest in innovation and sustainability, aiming to improve clinical outcomes and reduce the total cost of care for healthcare providers, worldwide.

Advanced Wound Care Product Portfolio

The section provides information on Mölnlycke Health Care’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Antimicrobial Dressings, Alginate Dressings and Superabsorbent Dressings
Advanced Wound Care Medical Devices: Negative Pressure Wound Therapy

Types of Acute Wounds Treated: Traumatic Wounds

Types of Chronic Wounds Treated: Pressure Ulcers and Venous Ulcers

Recent Developments

In June 2026, Mölnlycke Health Care announced a EUR 40 million investment in Mikkeli, Finland, and Oldham, UK facilities, to expand wound care production capacity, enhance sterilization processes, and improve supply chain resilience. This builds on the company’s prior expansions in the US and China, to support the growing demand for advanced wound care products while boosting efficiency and sustainability.

In May 2026, the company formed a majority-owned joint venture with Zhende Medical in China. The new entity, Mölnlycke Zhende, combines both companies’ advanced wound care portfolios and extensive commercial network to expand access to innovative products in China’s fast-growing market. This strategic partnership strengthens localization, enhances product offerings with technologies like Safetac®, and drives better patient outcomes in chronic and complex wounds.

To know more about the recent initiatives of Mölnlycke Health Care and other advanced wound care product providers, access full report.

6. Smith+Nephew

Company Overview

Smith+Nephew is focused on the development of products for orthopedics, ear, nose and throat. Within the advanced wound care segment, the company is actively engaged in the development of wound care dressings, bioengineered skins and dermal substitutes, and wound healing medical devices.

With distribution facilities spread across North America, Europe, and Asia, the company marks its global presence in more than 100 countries. The company continues to invest heavily in technologies such as negative pressure wound therapy systems and antimicrobial dressings designed to accelerate healing and reduce infection risks. Additionally, Smith+Nephew maintains strong partnerships with healthcare providers and research institutions, worldwide to advance clinical outcomes and expand its portfolio of wound management products.

Advanced Wound Care Product Portfolio

The section provides information on Smith+Nephew’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Antimicrobial Dressings, Hydrogel Dressings, Alginate Dressings, Hydrocolloid Dressings, Composite Dressings and Absorptive Wound Dressings
Advanced Wound Care Medical Devices: Negative Pressure Wound Therapy and Hydrotherapy
Advanced Wound Care Bioengineered Skin and Dermal Substitutes: Allografts

Types of Acute Wounds Treated: Surgical Wounds, Burns and Traumatic Wounds

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers and Other Types of Chronic Wounds

Recent Developments

In May 2026, the firm successfully launched the Renasys Edge Negative Pressure Wound Therapy System at the EWMA 2026 Conference in Bremen. Designed for ease of use, portability, and patient discretion, the system enhances clinical performance by promoting high patient compliance and improved wound healing outcomes. The modular design also eliminates annual servicing requirements while supporting greater patient self-care.

In March 2026, the firm launched its next-generation Allevyn Complete Care Foam Dressing, designed for both wound management and pressure injury prevention. The advanced five-layer dressing features proprietary technologies that locks in significantly more exudate, minimized leakage, enables longer wear times, and reduced the risk of pressure injuries through superior shear force dissipation.

To know more about the recent initiatives of Smith+Nephew and other advanced wound care product providers, access full report.

7. Solventum

Company Overview

Solventum is a recognized leader, particularly through its flagship V.A.C.® (Vacuum Assisted Closure) Negative Pressure Wound Therapy system. This pioneering technology creates an optimal healing environment by managing exudate, promoting granulation tissue formation, and protecting wounds from infection. It is widely used for chronic, acute, and hard-to-heal wounds, including diabetic foot ulcers, pressure injuries, and surgical incisions. The company offers a comprehensive portfolio including advanced wound dressings, antimicrobial products, and compression therapy. By integrating material science, digital capabilities, and patient-centered design, Solventum continues to drive advancements in wound management, addressing key challenges in healing while empowering healthcare providers worldwide.

Advanced Wound Care Product Portfolio

The section provides information on Solventum’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Foam Dressings, Antimicrobial Dressings, Hydrogel Dressings, Alginate Dressings, Hydrocolloid Dressings and Composite Dressings
Advanced Wound Care Medical Devices: Negative Pressure Wound Therapy and Skin Closure Systems / Adhesives
Advanced Wound Care Bioengineered Skin and Dermal Substitutes: Extracellular Matrix

Types of Acute Wounds Treated: Surgical Wounds, Burns and Traumatic Wounds

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers and Lymphostatic Ulcers

Recent Developments

In January 2026, Solventum launched the V.A.C.® Peel and Place Dressing in the UK for use in negative pressure wound therapy on closed surgical incisions and various wound types. This dressing simplifies the application process for clinicians, while significantly improving patient comfort. This is designed to be worn for up to seven days, and reduces the frequency of dressing changes, thereby minimising wound disruption, lowering infection risk, and enhancing overall healing outcomes.

In December 2025, Solventum completed the acquisition of Acera Surgical, a bioscience company specializing in fully engineered materials for regenerative wound care. This strategic move marks the company’s first acquisition and strengthens its advanced wound care portfolio with innovative synthetic tissue matrix technology for acute care settings. The acquisition is expected to accelerate the development and commercialization of next-generation regenerative products.

To know more about the recent initiatives of Solventum and other advanced wound care product providers, access full report.

8. Zimmer Biomet

Company Overview

Zimmer Biomet specializes in designing and manufacturing innovative orthopedic products in order to restore mobility and improve the quality of patient’s life. The company offers a comprehensive product portfolio designed for reconstruction of various body parts (including elbow, foot and ankle, hip, knee and shoulder).

Within the advanced wound care segment, the company currently offers wound care dressings, bioengineered skins and dermal substitutes, and wound healing medical devices. Zimmer has current business operations in more than 25 countries and sales operations in more than 100 countries. Committed to advancing patient outcomes, the firm continues to invest in next-generation technologies and evidence-based products that enhance healing and support in improving quality of life.

Advanced Wound Care Product Portfolio

The section provides information on Zimmer Biomet’s advanced wound care product portfolio:

Advanced Wound Care Dressings: Collagen Dressings
Advanced Wound Care Medical Devices: Pulsavac Plus and Pulsavac Plus AC Wound Debridement Systems
Advanced Wound Care Bioengineered Skin and Dermal Substitutes: Allografts

Types of Acute Wounds Treated: Surgical Wounds, Burns and Traumatic Wounds

Types of Chronic Wounds Treated: Diabetic Ulcers, Pressure Ulcers, Venous Ulcers, Oral Ulcers and Non-Healing Wounds

Recent Developments

In April 2026, Zimmer Biomet appointed Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer to drive its global innovation strategy. This strategic move is expected to strengthen the company’s focus on advanced technologies, including AI, robotics, and smart implants, aimed at reducing post-operative complications and enhancing wound healing outcomes in orthopedic procedures.

In February 2026, Zimmer Biomet showcased its latest innovations and presented new clinical data at the AAOS 2026 Annual Meeting, highlighting products for infection prevention alongside advanced orthopedic technologies. These efforts are further expected to strengthen the company’s wound care portfolio by emphasizing reducing complications and improved healing outcomes through integrated digital and smart implant technologies.

To know more about the recent initiatives of Zimmer Biomet and other advanced wound care product providers, access full report.

What About Other Advanced Wound Care Product Providers Around the World?

The above article features the top advanced wound care product providers selected from a pool of more than 240 product providers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources